Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Covington
US Department of Justice
Farmers Insurance
Daiichi Sankyo
Cantor Fitzgerald
Cerilliant
Mallinckrodt
Johnson and Johnson
Merck

Generated: October 17, 2017

DrugPatentWatch Database Preview

AVALIDE Drug Profile

« Back to Dashboard

What is the patent landscape for Avalide, and what generic Avalide alternatives are available?

Avalide is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in AVALIDE is hydrochlorothiazide; irbesartan. There are thirty-one drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; irbesartan profile page.

Summary for Tradename: AVALIDE

US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Clinical Trials: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:AVALIDE at DailyMed

Pharmacology for Tradename: AVALIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
AVALIDE
hydrochlorothiazide; irbesartan
TABLET;ORAL020758-001Sep 30, 1997DISCNYesNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
AVALIDE
hydrochlorothiazide; irbesartan
TABLET;ORAL020758-004Mar 15, 2005DISCNYesNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
AVALIDE
hydrochlorothiazide; irbesartan
TABLET;ORAL020758-002Sep 30, 1997ABRXYesYes► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
AVALIDE
hydrochlorothiazide; irbesartan
TABLET;ORAL020758-003Aug 31, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: AVALIDE

Paragraph IV (Patent) Challenges for AVALIDE

Drugname Dosage Strength RLD Submissiondate
irbesartan and hydrochlorothiazideTablets300 mg/25 mgAvalide6/6/2006
irbesartan and hydrochlorothiazideTablets150 mg/12.5 mg and 300 mg/12.5 mgAvalide11/10/2004
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
Cipla
Cerilliant
Colorcon
Citi
McKesson
Deloitte
Mallinckrodt
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot